(PharmaNewsWire.Com, April 04, 2017 ) Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
Publisher's analysts forecast the global factor VIII market to grow at a CAGR of 5.59% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-factor-viii-deficiency-treatment-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global factor VIII market for 2017-2021. To calculate the market size, the report considers the global demand for factor VIII.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Global Factor VIII Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
